JP2021045150A5 - - Google Patents

Download PDF

Info

Publication number
JP2021045150A5
JP2021045150A5 JP2020197751A JP2020197751A JP2021045150A5 JP 2021045150 A5 JP2021045150 A5 JP 2021045150A5 JP 2020197751 A JP2020197751 A JP 2020197751A JP 2020197751 A JP2020197751 A JP 2020197751A JP 2021045150 A5 JP2021045150 A5 JP 2021045150A5
Authority
JP
Japan
Prior art keywords
seq
peptide
fragment
variant
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020197751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021045150A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021045150A publication Critical patent/JP2021045150A/ja
Publication of JP2021045150A5 publication Critical patent/JP2021045150A5/ja
Priority to JP2022203854A priority Critical patent/JP2023030082A/ja
Pending legal-status Critical Current

Links

JP2020197751A 2016-04-06 2020-11-30 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ Pending JP2021045150A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022203854A JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662319141P 2016-04-06 2016-04-06
US62/319,141 2016-04-06
GB1605872.9 2016-04-06
GB201605872 2016-04-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018552196A Division JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022203854A Division JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Publications (2)

Publication Number Publication Date
JP2021045150A JP2021045150A (ja) 2021-03-25
JP2021045150A5 true JP2021045150A5 (https=) 2021-08-05

Family

ID=58503590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552196A Expired - Fee Related JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020197751A Pending JP2021045150A (ja) 2016-04-06 2020-11-30 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2022203854A Pending JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018552196A Expired - Fee Related JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022203854A Pending JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Country Status (19)

Country Link
US (10) US10596240B2 (https=)
EP (2) EP4219524A3 (https=)
JP (3) JP6989136B2 (https=)
KR (2) KR102411975B1 (https=)
CN (1) CN109071605A (https=)
AU (2) AU2017247607B2 (https=)
BR (1) BR112018070067A2 (https=)
CA (1) CA3020162A1 (https=)
CL (4) CL2018002827A1 (https=)
CO (1) CO2018011889A2 (https=)
CR (1) CR20180530A (https=)
IL (1) IL262081A (https=)
MA (1) MA44605A (https=)
MX (1) MX2018012152A (https=)
MY (1) MY197258A (https=)
PE (1) PE20181896A1 (https=)
PH (1) PH12018502108A1 (https=)
SG (3) SG10202110335PA (https=)
TW (3) TWI782375B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173666A1 (en) * 2020-04-14 2021-10-21 Claude Perreault Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
CN115290806B (zh) * 2022-08-01 2024-05-28 宁波工程学院 一种亲水作用和阳离子交换的固相萃取生物胺的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999046276A1 (en) * 1998-03-13 1999-09-16 Genos Biosciences, Inc. Zap-1 tumor associated genes and their uses
EP1239866A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
WO2002066501A2 (en) * 2001-01-02 2002-08-29 Hybrigenics PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002365187A1 (en) * 2001-11-07 2003-07-24 Mannkind Corporation Epitope synchronization in antigen presenting cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
EP1629119A2 (en) * 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2458014A1 (en) 2010-09-07 2012-05-30 Rijksuniversiteit Groningen Prognostic markers for acute myeloid leukemia (AML)
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013009818A2 (en) * 2011-07-11 2013-01-17 Gevo, Inc. High-performance ketol-acid reductoisomerases
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
CN104080797A (zh) * 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US9254311B2 (en) * 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
RS61173B1 (sr) * 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
WO2015150491A1 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
ES2702676T3 (es) * 2014-04-01 2019-03-04 Inst Nat Sante Rech Med Péptido de donante aislado derivado de MHC y usos del mismo
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2017174645A1 (en) * 2016-04-06 2017-10-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Similar Documents

Publication Publication Date Title
JP2020191862A5 (https=)
JP2020198875A5 (https=)
JP2020182458A5 (https=)
JP2021101700A5 (https=)
JP2024041841A5 (https=)
JP2019516663A5 (https=)
JP2024099580A5 (https=)
JP6639233B2 (ja) Mage−a1を認識する高結合活性結合分子
JP2019502360A5 (https=)
JP2020516681A5 (https=)
JP2018529320A5 (https=)
JP2019511214A5 (https=)
JP2018510628A5 (https=)
JP2021535900A5 (https=)
JP2019513005A5 (https=)
JP2019536426A5 (https=)
JP2019510465A5 (https=)
JP2019515650A5 (https=)
JP2018536383A5 (https=)
JP2021514178A5 (https=)
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2020506690A5 (https=)
JP2019515653A5 (https=)
JP2021528046A5 (https=)
JP2022502015A5 (https=)